Share Price and Basic Stock Data
Last Updated: December 12, 2025, 6:05 am
| PEG Ratio | -8.94 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aster DM Healthcare Ltd operates in the competitive healthcare sector, focusing on hospitals and medical services. As of the latest reporting period, the company’s market capitalization stood at ₹32,054 Cr, with its share price at ₹619. The revenue trajectory has been somewhat volatile, with sales recorded at ₹2,994 Cr for FY 2023, a noticeable decline from ₹10,253 Cr in FY 2022. However, the trailing twelve months (TTM) revenue has shown a recovery, standing at ₹4,214 Cr, indicating a potential rebound. The quarterly figures exhibit a gradual increase, especially in the latter half of 2023, where sales rose from ₹841 Cr in June 2023 to ₹929 Cr by September 2023. This upward trend is promising, suggesting that the company may be recovering from previous operational challenges. Nevertheless, the overall revenue figures indicate that Aster DM Healthcare is navigating through a complex landscape, balancing growth ambitions with market realities.
Profitability and Efficiency Metrics
Profitability appears to be an area of concern for Aster DM Healthcare, with a reported net profit of ₹349 Cr for the trailing twelve months, translating to a P/E ratio of 87.3. This high ratio signals that investors might be paying a premium for earnings that have not consistently grown. Operating profit margins (OPM) have shown some improvement, rising to 19% in the latest quarter, up from 15% in FY 2023. However, the overall operating profit for FY 2023 was only ₹447 Cr, which is a stark contrast to the ₹1,533 Cr recorded in FY 2022. The company’s return on equity (ROE) is at a modest 8.26%, and return on capital employed (ROCE) at 10.7%, indicating that while there is some efficiency, it remains below optimal levels. These metrics suggest that Aster DM Healthcare is under pressure to enhance its profitability and operational efficiency to meet shareholder expectations.
Balance Sheet Strength and Financial Ratios
The balance sheet of Aster DM Healthcare reveals a mixed picture, with total borrowings amounting to ₹2,089 Cr against reserves of ₹4,015 Cr. This results in a comfortable debt-to-equity ratio of 0.18, indicating that the company is not excessively leveraged. Furthermore, with an interest coverage ratio (ICR) of 7.37, Aster DM Healthcare seems well-positioned to meet its interest obligations. However, the cash conversion cycle (CCC) of -107 days suggests that the company is effectively managing its receivables and payables, which is a positive sign. Nevertheless, the relatively high price-to-book value ratio of 7.06x raises concerns about valuation, particularly given the modest return metrics. Investors should be cautious about the balance between leveraging growth and maintaining financial health, especially in a capital-intensive industry like healthcare.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aster DM Healthcare indicates a diversified investor base, with promoters holding 40.39%, foreign institutional investors (FIIs) at 18.72%, and domestic institutional investors (DIIs) at 26.32%. This distribution reflects a healthy level of institutional interest, which often signals confidence in the company’s potential. However, it’s worth noting that promoter holdings have remained relatively stable, while FIIs have seen a gradual decline from 42.49% in December 2022 to the current levels. This shift could suggest a cautious sentiment among foreign investors, which may be influenced by the company’s recent performance and profitability concerns. The public shareholding stands at 14.33%, which, while not negligible, could indicate room for greater retail investor engagement. Overall, the shareholding dynamics suggest a blend of confidence and caution among different investor classes.
Outlook, Risks, and Final Insight
Looking ahead, Aster DM Healthcare faces a dual-edged sword of opportunities and challenges. On one hand, the increasing demand for healthcare services in India, fueled by a growing population and rising health awareness, presents significant growth prospects. On the other hand, the company must navigate its profitability issues, high valuation metrics, and the pressure to improve operational efficiency. Risks such as regulatory changes, rising operational costs, and competition from both established and emerging players could impact its performance. Investors should weigh these factors carefully, considering both the potential for recovery and the inherent risks in the healthcare sector. Aster DM Healthcare’s ability to enhance profitability while managing its balance sheet effectively will be critical in determining its future trajectory. Overall, while the stock presents opportunities, a measured approach is advisable given the current financial landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Aster DM Healthcare Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 43.2 Cr. | 129 | 195/120 | 8.81 | 117 | 2.72 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 21.5 Cr. | 20.5 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 9.42 Cr. | 9.11 | 20.8/9.10 | 105 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 113 Cr. | 60.5 | 98.7/55.2 | 25.0 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 21.0 Cr. | 3.88 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,145.86 Cr | 753.34 | 93.45 | 99.39 | 0.34% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,662 | 2,816 | 3,192 | 807 | 841 | 929 | 955 | 974 | 1,002 | 1,086 | 1,050 | 1,000 | 1,078 |
| Expenses | 2,370 | 2,498 | 2,743 | 687 | 722 | 787 | 805 | 817 | 841 | 869 | 864 | 818 | 876 |
| Operating Profit | 292 | 319 | 449 | 120 | 119 | 142 | 149 | 156 | 161 | 217 | 186 | 182 | 202 |
| OPM % | 11% | 11% | 14% | 15% | 14% | 15% | 16% | 16% | 16% | 20% | 18% | 18% | 19% |
| Other Income | 37 | 18 | 10 | 149 | -17 | -64 | 153 | -40 | 5,120 | 35 | 9 | 5 | 29 |
| Interest | 69 | 77 | 87 | 25 | 25 | 30 | 25 | 30 | 29 | 31 | 31 | 32 | 31 |
| Depreciation | 175 | 189 | 198 | 54 | 51 | 54 | 57 | 58 | 60 | 62 | 62 | 64 | 63 |
| Profit before tax | 85 | 71 | 173 | 190 | 26 | -7 | 220 | 28 | 5,191 | 159 | 102 | 91 | 136 |
| Tax % | 6% | 23% | 8% | 4% | 24% | 120% | 5% | 108% | 1% | 33% | 37% | 6% | 31% |
| Net Profit | 80 | 54 | 159 | 183 | 20 | -15 | 209 | -2 | 5,152 | 106 | 64 | 86 | 94 |
| EPS in Rs | 1.37 | 0.93 | 2.79 | 3.42 | 0.10 | -0.62 | 3.59 | -0.48 | 103.00 | 1.94 | 1.14 | 1.58 | 1.65 |
Last Updated: August 1, 2025, 11:55 pm
Below is a detailed analysis of the quarterly data for Aster DM Healthcare Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,078.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,000.00 Cr. (Mar 2025) to 1,078.00 Cr., marking an increase of 78.00 Cr..
- For Expenses, as of Jun 2025, the value is 876.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 818.00 Cr. (Mar 2025) to 876.00 Cr., marking an increase of 58.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 202.00 Cr.. The value appears strong and on an upward trend. It has increased from 182.00 Cr. (Mar 2025) to 202.00 Cr., marking an increase of 20.00 Cr..
- For OPM %, as of Jun 2025, the value is 19.00%. The value appears strong and on an upward trend. It has increased from 18.00% (Mar 2025) to 19.00%, marking an increase of 1.00%.
- For Other Income, as of Jun 2025, the value is 29.00 Cr.. The value appears strong and on an upward trend. It has increased from 5.00 Cr. (Mar 2025) to 29.00 Cr., marking an increase of 24.00 Cr..
- For Interest, as of Jun 2025, the value is 31.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 32.00 Cr. (Mar 2025) to 31.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 63.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 64.00 Cr. (Mar 2025) to 63.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 136.00 Cr.. The value appears strong and on an upward trend. It has increased from 91.00 Cr. (Mar 2025) to 136.00 Cr., marking an increase of 45.00 Cr..
- For Tax %, as of Jun 2025, the value is 31.00%. The value appears to be increasing, which may not be favorable. It has increased from 6.00% (Mar 2025) to 31.00%, marking an increase of 25.00%.
- For Net Profit, as of Jun 2025, the value is 94.00 Cr.. The value appears strong and on an upward trend. It has increased from 86.00 Cr. (Mar 2025) to 94.00 Cr., marking an increase of 8.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.65. The value appears strong and on an upward trend. It has increased from 1.58 (Mar 2025) to 1.65, marking an increase of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 22, 2025, 5:25 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,871 | 3,876 | 5,250 | 5,931 | 6,721 | 7,963 | 8,652 | 8,608 | 10,253 | 2,994 | 3,699 | 4,138 | 4,214 |
| Expenses | 2,421 | 3,370 | 4,805 | 5,582 | 6,089 | 6,886 | 7,187 | 7,506 | 8,720 | 2,547 | 3,124 | 3,384 | 3,428 |
| Operating Profit | 451 | 506 | 445 | 349 | 632 | 1,077 | 1,465 | 1,103 | 1,533 | 447 | 575 | 754 | 786 |
| OPM % | 16% | 13% | 8% | 6% | 9% | 14% | 17% | 13% | 15% | 15% | 16% | 18% | 19% |
| Other Income | 19 | 23 | 25 | 453 | 177 | -155 | -158 | 53 | 51 | 353 | 32 | 5,169 | 78 |
| Interest | 48 | 79 | 189 | 371 | 204 | 205 | 391 | 334 | 307 | 96 | 119 | 133 | 125 |
| Depreciation | 111 | 144 | 243 | 322 | 298 | 306 | 586 | 618 | 641 | 192 | 220 | 249 | 252 |
| Profit before tax | 310 | 306 | 38 | 108 | 308 | 410 | 330 | 205 | 637 | 511 | 268 | 5,542 | 488 |
| Tax % | 9% | 11% | 78% | 10% | 8% | 10% | 5% | 13% | 6% | 7% | 21% | 2% | |
| Net Profit | 284 | 272 | 8 | 98 | 282 | 367 | 315 | 178 | 601 | 475 | 212 | 5,408 | 349 |
| EPS in Rs | 4.69 | 7.00 | 0.20 | 2.52 | 5.32 | 6.59 | 5.54 | 2.96 | 10.53 | 8.51 | 2.59 | 107.66 | 6.31 |
| Dividend Payout % | 35% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 4,637% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -4.23% | -97.06% | 1125.00% | 187.76% | 30.14% | -14.17% | -43.49% | 237.64% | -20.97% | -55.37% | 2450.94% |
| Change in YoY Net Profit Growth (%) | 0.00% | -92.83% | 1222.06% | -937.24% | -157.61% | -44.31% | -29.32% | 281.13% | -258.61% | -34.40% | 2506.31% |
Aster DM Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -14% |
| 3 Years: | -26% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | -7% |
| 3 Years: | -17% |
| TTM: | 82% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 38% |
| 3 Years: | 38% |
| 1 Year: | 56% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 8% |
| 3 Years: | 7% |
| Last Year: | 8% |
Last Updated: September 4, 2025, 11:55 pm
Balance Sheet
Last Updated: December 4, 2025, 12:59 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 375 | 389 | 403 | 403 | 505 | 505 | 497 | 497 | 500 | 500 | 500 | 500 | 518 |
| Reserves | 536 | 1,096 | 17 | 1,472 | 2,327 | 2,709 | 2,775 | 2,875 | 3,080 | 3,574 | 3,686 | 2,554 | 4,015 |
| Borrowings | 886 | 1,091 | 3,321 | 2,758 | 2,352 | 2,788 | 5,605 | 4,804 | 5,282 | 6,075 | 1,758 | 2,392 | 2,089 |
| Other Liabilities | 1,097 | 1,834 | 2,003 | 2,171 | 2,296 | 2,926 | 3,528 | 3,444 | 3,661 | 4,687 | 12,039 | 1,154 | 1,186 |
| Total Liabilities | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,983 | 6,600 | 7,808 |
| Fixed Assets | 1,087 | 2,237 | 2,507 | 3,520 | 3,738 | 4,289 | 7,124 | 6,749 | 7,009 | 9,052 | 3,175 | 3,920 | 4,024 |
| CWIP | 357 | 197 | 358 | 290 | 402 | 550 | 736 | 934 | 998 | 279 | 170 | 293 | 401 |
| Investments | 7 | 3 | 39 | 32 | 38 | 22 | 34 | 63 | 45 | 80 | 17 | 245 | 1,184 |
| Other Assets | 1,442 | 1,972 | 2,839 | 2,962 | 3,302 | 4,067 | 4,511 | 3,874 | 4,470 | 5,425 | 14,620 | 2,142 | 2,199 |
| Total Assets | 2,894 | 4,409 | 5,743 | 6,804 | 7,479 | 8,928 | 12,405 | 11,620 | 12,521 | 14,836 | 17,983 | 6,600 | 7,808 |
Below is a detailed analysis of the balance sheet data for Aster DM Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 518.00 Cr.. The value appears strong and on an upward trend. It has increased from 500.00 Cr. (Mar 2025) to 518.00 Cr., marking an increase of 18.00 Cr..
- For Reserves, as of Sep 2025, the value is 4,015.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,554.00 Cr. (Mar 2025) to 4,015.00 Cr., marking an increase of 1,461.00 Cr..
- For Borrowings, as of Sep 2025, the value is 2,089.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 2,392.00 Cr. (Mar 2025) to 2,089.00 Cr., marking a decrease of 303.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 1,186.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,154.00 Cr. (Mar 2025) to 1,186.00 Cr., marking an increase of 32.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 7,808.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,600.00 Cr. (Mar 2025) to 7,808.00 Cr., marking an increase of 1,208.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 4,024.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,920.00 Cr. (Mar 2025) to 4,024.00 Cr., marking an increase of 104.00 Cr..
- For CWIP, as of Sep 2025, the value is 401.00 Cr.. The value appears strong and on an upward trend. It has increased from 293.00 Cr. (Mar 2025) to 401.00 Cr., marking an increase of 108.00 Cr..
- For Investments, as of Sep 2025, the value is 1,184.00 Cr.. The value appears strong and on an upward trend. It has increased from 245.00 Cr. (Mar 2025) to 1,184.00 Cr., marking an increase of 939.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,199.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,142.00 Cr. (Mar 2025) to 2,199.00 Cr., marking an increase of 57.00 Cr..
- For Total Assets, as of Sep 2025, the value is 7,808.00 Cr.. The value appears strong and on an upward trend. It has increased from 6,600.00 Cr. (Mar 2025) to 7,808.00 Cr., marking an increase of 1,208.00 Cr..
Notably, the Reserves (4,015.00 Cr.) exceed the Borrowings (2,089.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -435.00 | 505.00 | 442.00 | 347.00 | 630.00 | -1.00 | -4.00 | -3.00 | -4.00 | 441.00 | 574.00 | 752.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 86 | 83 | 93 | 79 | 84 | 93 | 100 | 86 | 72 | 285 | 23 | 23 |
| Inventory Days | 71 | 93 | 92 | 102 | 111 | 110 | 138 | 122 | 129 | 612 | 44 | 36 |
| Days Payable | 176 | 178 | 187 | 151 | 150 | 153 | 303 | 290 | 267 | 1,400 | 183 | 166 |
| Cash Conversion Cycle | -18 | -2 | -1 | 30 | 45 | 50 | -65 | -83 | -66 | -503 | -116 | -107 |
| Working Capital Days | 61 | 69 | 68 | 6 | 59 | 28 | 8 | 5 | 5 | -21 | 272 | -32 |
| ROCE % | 18% | 14% | 6% | 1% | 7% | 13% | 12% | 6% | 10% | 3% | 4% | 11% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| HDFC Small Cap Fund | 23,927,134 | 4.22 | 1622.38 | N/A | N/A | N/A |
| Kotak Small Cap Fund | 11,757,234 | 4.42 | 797.2 | N/A | N/A | N/A |
| Quant Small Cap Fund | 11,305,160 | 2.51 | 766.55 | 1,758,485 | 2025-12-08 07:20:44 | 542.89% |
| Nippon India Small Cap Fund | 9,522,707 | 0.94 | 645.69 | N/A | N/A | N/A |
| SBI Contra Fund | 9,199,605 | 1.27 | 623.78 | N/A | N/A | N/A |
| Kotak Midcap Fund | 5,738,292 | 0.64 | 389.08 | N/A | N/A | N/A |
| Franklin India Small Cap Fund | 5,618,134 | 2.76 | 380.94 | N/A | N/A | N/A |
| HDFC Childrens Fund | 3,759,174 | 2.42 | 254.89 | N/A | N/A | N/A |
| HSBC Small Cap Fund | 3,574,000 | 1.46 | 242.34 | N/A | N/A | N/A |
| Franklin India Opportunities Fund | 2,780,440 | 2.3 | 188.53 | 1,489,839 | 2025-12-08 05:14:17 | 86.63% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 107.98 | 2.60 | 8.54 | 10.58 | 2.97 |
| Diluted EPS (Rs.) | 107.85 | 2.60 | 8.53 | 10.57 | 2.97 |
| Cash EPS (Rs.) | 113.62 | 8.87 | 25.12 | 24.96 | 15.93 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 68.63 | 100.70 | 89.81 | 90.15 | 77.14 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 68.63 | 100.70 | 89.81 | 90.15 | 77.14 |
| Revenue From Operations / Share (Rs.) | 82.85 | 74.05 | 238.89 | 206.21 | 173.19 |
| PBDIT / Share (Rs.) | 18.27 | 12.07 | 32.90 | 30.85 | 22.39 |
| PBIT / Share (Rs.) | 13.29 | 7.66 | 17.28 | 17.97 | 9.96 |
| PBT / Share (Rs.) | 9.81 | 5.46 | 10.69 | 12.80 | 4.05 |
| Net Profit / Share (Rs.) | 108.64 | 4.46 | 9.49 | 12.08 | 3.51 |
| NP After MI And SOA / Share (Rs.) | 107.66 | 2.59 | 8.51 | 10.58 | 2.97 |
| PBDIT Margin (%) | 22.05 | 16.29 | 13.77 | 14.96 | 12.92 |
| PBIT Margin (%) | 16.04 | 10.34 | 7.23 | 8.71 | 5.75 |
| PBT Margin (%) | 11.83 | 7.36 | 4.47 | 6.20 | 2.34 |
| Net Profit Margin (%) | 131.13 | 6.02 | 3.97 | 5.85 | 2.02 |
| NP After MI And SOA Margin (%) | 129.94 | 3.49 | 3.56 | 5.12 | 1.71 |
| Return on Networth / Equity (%) | 156.87 | 2.83 | 10.43 | 13.30 | 4.38 |
| Return on Capital Employeed (%) | 11.59 | 5.71 | 8.44 | 9.93 | 5.86 |
| Return On Assets (%) | 81.40 | 0.71 | 2.85 | 4.19 | 1.26 |
| Long Term Debt / Equity (X) | 0.14 | 0.09 | 0.32 | 0.37 | 0.52 |
| Total Debt / Equity (X) | 0.18 | 0.14 | 0.56 | 0.55 | 0.56 |
| Asset Turnover Ratio (%) | 0.33 | 0.22 | 0.18 | 0.14 | 0.09 |
| Current Ratio (X) | 2.16 | 1.25 | 1.06 | 1.15 | 1.14 |
| Quick Ratio (X) | 2.06 | 1.25 | 0.77 | 0.86 | 0.86 |
| Inventory Turnover Ratio (X) | 40.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 114.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 109.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | -14.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | -9.73 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 7.37 | 5.46 | 4.99 | 5.97 | 3.79 |
| Interest Coverage Ratio (Post Tax) (X) | 4.28 | 2.96 | 2.44 | 3.34 | 1.59 |
| Enterprise Value (Cr.) | 23702.29 | 21464.85 | 14334.72 | 12129.54 | 8918.86 |
| EV / Net Operating Revenue (X) | 5.73 | 5.80 | 1.20 | 1.18 | 1.04 |
| EV / EBITDA (X) | 25.97 | 35.61 | 8.72 | 7.91 | 8.02 |
| MarketCap / Net Operating Revenue (X) | 5.85 | 5.53 | 1.01 | 0.95 | 0.79 |
| Retention Ratios (%) | -14.80 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 7.06 | 4.48 | 2.96 | 2.48 | 2.02 |
| Price / Net Operating Revenue (X) | 5.85 | 5.53 | 1.01 | 0.95 | 0.79 |
| EarningsYield | 0.22 | 0.01 | 0.03 | 0.05 | 0.02 |
After reviewing the key financial ratios for Aster DM Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 107.98. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 107.98, marking an increase of 105.38.
- For Diluted EPS (Rs.), as of Mar 25, the value is 107.85. This value is within the healthy range. It has increased from 2.60 (Mar 24) to 107.85, marking an increase of 105.25.
- For Cash EPS (Rs.), as of Mar 25, the value is 113.62. This value is within the healthy range. It has increased from 8.87 (Mar 24) to 113.62, marking an increase of 104.75.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.63. It has decreased from 100.70 (Mar 24) to 68.63, marking a decrease of 32.07.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 68.63. It has decreased from 100.70 (Mar 24) to 68.63, marking a decrease of 32.07.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 82.85. It has increased from 74.05 (Mar 24) to 82.85, marking an increase of 8.80.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 18.27. This value is within the healthy range. It has increased from 12.07 (Mar 24) to 18.27, marking an increase of 6.20.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.29. This value is within the healthy range. It has increased from 7.66 (Mar 24) to 13.29, marking an increase of 5.63.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.81. This value is within the healthy range. It has increased from 5.46 (Mar 24) to 9.81, marking an increase of 4.35.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 108.64. This value is within the healthy range. It has increased from 4.46 (Mar 24) to 108.64, marking an increase of 104.18.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 107.66. This value is within the healthy range. It has increased from 2.59 (Mar 24) to 107.66, marking an increase of 105.07.
- For PBDIT Margin (%), as of Mar 25, the value is 22.05. This value is within the healthy range. It has increased from 16.29 (Mar 24) to 22.05, marking an increase of 5.76.
- For PBIT Margin (%), as of Mar 25, the value is 16.04. This value is within the healthy range. It has increased from 10.34 (Mar 24) to 16.04, marking an increase of 5.70.
- For PBT Margin (%), as of Mar 25, the value is 11.83. This value is within the healthy range. It has increased from 7.36 (Mar 24) to 11.83, marking an increase of 4.47.
- For Net Profit Margin (%), as of Mar 25, the value is 131.13. This value exceeds the healthy maximum of 10. It has increased from 6.02 (Mar 24) to 131.13, marking an increase of 125.11.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 129.94. This value exceeds the healthy maximum of 20. It has increased from 3.49 (Mar 24) to 129.94, marking an increase of 126.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 156.87. This value is within the healthy range. It has increased from 2.83 (Mar 24) to 156.87, marking an increase of 154.04.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.59. This value is within the healthy range. It has increased from 5.71 (Mar 24) to 11.59, marking an increase of 5.88.
- For Return On Assets (%), as of Mar 25, the value is 81.40. This value is within the healthy range. It has increased from 0.71 (Mar 24) to 81.40, marking an increase of 80.69.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 0.2. It has increased from 0.09 (Mar 24) to 0.14, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.18. This value is within the healthy range. It has increased from 0.14 (Mar 24) to 0.18, marking an increase of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.33. It has increased from 0.22 (Mar 24) to 0.33, marking an increase of 0.11.
- For Current Ratio (X), as of Mar 25, the value is 2.16. This value is within the healthy range. It has increased from 1.25 (Mar 24) to 2.16, marking an increase of 0.91.
- For Quick Ratio (X), as of Mar 25, the value is 2.06. This value exceeds the healthy maximum of 2. It has increased from 1.25 (Mar 24) to 2.06, marking an increase of 0.81.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 40.80. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 40.80, marking an increase of 40.80.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 114.80. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 114.80, marking an increase of 114.80.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 109.73. This value exceeds the healthy maximum of 50. It has increased from 0.00 (Mar 24) to 109.73, marking an increase of 109.73.
- For Earning Retention Ratio (%), as of Mar 25, the value is -14.80. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -14.80, marking a decrease of 14.80.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is -9.73. This value is below the healthy minimum of 40. It has decreased from 0.00 (Mar 24) to -9.73, marking a decrease of 9.73.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.37. This value is within the healthy range. It has increased from 5.46 (Mar 24) to 7.37, marking an increase of 1.91.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.28. This value is within the healthy range. It has increased from 2.96 (Mar 24) to 4.28, marking an increase of 1.32.
- For Enterprise Value (Cr.), as of Mar 25, the value is 23,702.29. It has increased from 21,464.85 (Mar 24) to 23,702.29, marking an increase of 2,237.44.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 5.73. This value exceeds the healthy maximum of 3. It has decreased from 5.80 (Mar 24) to 5.73, marking a decrease of 0.07.
- For EV / EBITDA (X), as of Mar 25, the value is 25.97. This value exceeds the healthy maximum of 15. It has decreased from 35.61 (Mar 24) to 25.97, marking a decrease of 9.64.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 5.85. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 5.85, marking an increase of 0.32.
- For Retention Ratios (%), as of Mar 25, the value is -14.80. This value is below the healthy minimum of 30. It has decreased from 0.00 (Mar 24) to -14.80, marking a decrease of 14.80.
- For Price / BV (X), as of Mar 25, the value is 7.06. This value exceeds the healthy maximum of 3. It has increased from 4.48 (Mar 24) to 7.06, marking an increase of 2.58.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 5.85. This value exceeds the healthy maximum of 3. It has increased from 5.53 (Mar 24) to 5.85, marking an increase of 0.32.
- For EarningsYield, as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.22, marking an increase of 0.21.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aster DM Healthcare Ltd:
- Net Profit Margin: 131.13%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.59% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 156.87% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.28
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.06
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 87 (Industry average Stock P/E: 93.45)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.18
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 131.13%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Bengaluru Kerala 560027 | cs@asterdmhealthcare.com http://www.asterdmhealthcare.in |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Azad Moopen | Founder Chairman & Mng. Director |
| Ms. Alisha Moopen | Deputy Managing Director |
| Mr. Daniel Robert Mintz | Non Executive Director |
| Mr. T J Wilson | Non Executive Director |
| Mr. Shamsudheen Bin Mohideen Mammu Haji | Non Executive Director |
| Dr. Zeba Azad Moopen | Non Executive Director |
| Mr. Anoop Moopen | Non Executive Director |
| Ms. Purana Housdurgamvijaya Deepti | Independent Director |
| Mr. Chenayappillil John George | Independent Director |
| Mr. Maniedath Madhavan Nambiar | Independent Director |
| Mr. Sunil Theckath Vasudevan | Independent Director |
| Dr. James Mathew | Independent Director |
| Mr. Emmanuel David Gootam | Independent Director |
FAQ
What is the intrinsic value of Aster DM Healthcare Ltd?
Aster DM Healthcare Ltd's intrinsic value (as of 12 December 2025) is 507.11 which is 17.68% lower the current market price of 616.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 31,937 Cr. market cap, FY2025-2026 high/low of 732/386, reserves of ₹4,015 Cr, and liabilities of 7,808 Cr.
What is the Market Cap of Aster DM Healthcare Ltd?
The Market Cap of Aster DM Healthcare Ltd is 31,937 Cr..
What is the current Stock Price of Aster DM Healthcare Ltd as on 12 December 2025?
The current stock price of Aster DM Healthcare Ltd as on 12 December 2025 is 616.
What is the High / Low of Aster DM Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aster DM Healthcare Ltd stocks is 732/386.
What is the Stock P/E of Aster DM Healthcare Ltd?
The Stock P/E of Aster DM Healthcare Ltd is 87.0.
What is the Book Value of Aster DM Healthcare Ltd?
The Book Value of Aster DM Healthcare Ltd is 87.5.
What is the Dividend Yield of Aster DM Healthcare Ltd?
The Dividend Yield of Aster DM Healthcare Ltd is 0.81 %.
What is the ROCE of Aster DM Healthcare Ltd?
The ROCE of Aster DM Healthcare Ltd is 10.7 %.
What is the ROE of Aster DM Healthcare Ltd?
The ROE of Aster DM Healthcare Ltd is 8.26 %.
What is the Face Value of Aster DM Healthcare Ltd?
The Face Value of Aster DM Healthcare Ltd is 10.0.